Abstract
In addition to a clear commitment to an overarching strategic goal, strategic management of the early innovation phase in the field of life sciences requires two key capabilities: The skills and tools for sourcing additional early lead candidates, as well as the organizational and technological capability to master complexity. Both of Bayer’s life science subgroups (Bayer CropScience and Bayer HealthCare) use a stage-gate process for continuously assessing the progress, value and probability of success of their early innovation projects. The stage-gate process used is divided into four major stages: Stages 0 to 2 address the early innovation phase, stages 3 and 4 address the later phases of product development and launch. To facilitate sound decision-making, the review process is guided by a strategic process of decision analysis, using criteria like market potential, likelihood of success, degree of innovation, and costs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bayer Annual Report (2010) http://www.annualreport2010.bayer.com/
Bayer Annual Report (2011) http://www.annualreport2011.bayer.com/
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Plischke, W., Heubach, J., Maier, S.M. (2014). Bayer: Strategic Management of the Early Innovation Phase. In: Gassmann, O., Schweitzer, F. (eds) Management of the Fuzzy Front End of Innovation. Springer, Cham. https://doi.org/10.1007/978-3-319-01056-4_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-01056-4_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-01055-7
Online ISBN: 978-3-319-01056-4
eBook Packages: Business and EconomicsBusiness and Management (R0)